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Abstract: Today schistosomiasis, caused mainly by the three major schistosome species (S. 
mansoni, S. haematobium and S. japonicum), has for many decades and still continues to be on a 
rapid and swift rise globally, claiming thousands of lives every year and leaving 800 million peo-
ple at the risk of infection. Due to the high prevalence of this disease and the steady increase in the 
infection rates, praziquantel (PZQ) remains the only effective drug against this acute disease al-
though it has no effect on the juvenile schistosome parasite. However, no significant approaches 
have been made in recent years in the discovery of new or alternative drugs and unfortunately, re-
sistance to this drug has been reported in some parts of the world. Therefore, it is imperative to 
develop a new drug for this debilitating disease. In this review, a brief history of past, present, and 
new promising anti-schistosomal drugs is presented.
Keywords: Drugs, praziquantel, schistosomiasis, Schistosoma mansoni, Schistosoma haematobium, schistosome. 
1. INTRODUCTION 
Schistosomiasis continues to be one of the most signifi-
cant water and vector-borne diseases from a universal public 
health disposition [1]. This disease is said to follow hook-
worm infections as the second most prevalent Neglected 
Tropical Disease (NTD) in sub-Saharan Africa [2]. Cur-
rently, schistosomiasis is a debilitating disease that is trans-
mitted in 78 developing countries and affects over 200 mil-
lion people globally [3, 4]. In the sub-Saharan African region 
alone, 193 million cases occur mostly due to bad sanitation, 
poor treatment, and very few control programs. The disease 
is responsible for the loss of 10.4 million disability adjusted 
life years (DALYs) and accounts for over 280,000 deaths 
annually [5]. Additionally, over 800 million people are still 
vulnerable to this disease [6].  
Schistosomiasis, also referred to as bilharziasis [7], is 
caused by parasitic trematode flatworms found in fresh water 
belonging to the genus Schistosoma [8]. The lifecycle starts 
asexually once schistosome eggs are voided into freshwater 
with the urine or faeces of the definitive host (human) and 
miracidia are produced from the eggs. These swim freely in 
water and find their way into the tissue of the intermediate  
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host (snail). In the snail, the miracidia transform into sporo-
cysts that produce many cercariae through asexual reproduc-
tion. The infection starts when humans are exposed to waters 
infested with cercariae, which have the ability to penetrate 
human skin. Once this takes place, the cercariae lose their 
bifurcated tails and metamorphose into schistosomulae, 
which migrate to various tissues such as the heart, liver and 
lungs. In the liver, the schistosomulae undergo rapid growth 
and mature into adult worms. Eggs are then produced from 
mating adults, which are either shed in human excreta, or 
lodged in various tissues that ultimately lead to various com-
plications of the disease such as genital, pulmonary, hepato-
intestinal or neuro-schistosomiasis and other clinical out-
comes such as gastrointestinal and hepatic pathologies, 
anaemia, caloric malnutrition as well as a heightened risk to 
HIV/AIDS and cancer of the bladder. The worms are able to 
produce several hundred eggs daily which are all capable of 
developing into schistosomes. S. mansoni adults lay about 
200-300 laterally-spined ovoid eggs daily while S. 
haematobium and S. japonicum parasites lay 20-200 round, 
terminally-spined eggs and 500-3500 small and round later-
ally-spined eggs respectively. As discussed by Hsieh and 
Mentink-Kane [9], the parasite can stay in host blood vessels 
for many years and this parasitic ability highlights the Schis-
tosoma species’ aptitude for evasion and prolonged existence 
in the host immune system.   
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Not until 1984 when the World Health Organisation Ex-
pert Committee proposed chemotherapy, elimination of 
snails was often used in tackling this chronic debilitating 
disease [10]. Chemotherapy remains the only means for 
schistosomiasis control but this has relied solely on one sin-
gle effective treatment, praziquantel (PZQ), which is now 
deemed unsatisfactory [11-13]. In recent times, not much 
approach has been made to develop new drugs for this dis-
ease because pharmaceutical companies snub diseases affect-
ing poor nations hence, schistosomiasis was referred to as 
one neglected tropical diseases. Over the last few decades, 
many drugs have been used in the treatment of schistosomia-
sis. In this article, past, recent and currently-used schis-
tosomicides are reviewed and the question of how close we 
are in the development of effective treatment against this 
debilitating disease is addressed. 
2. PRAZIQUANTEL (PZQ) 
Praziquantel-(2-cyclohexylcarbonyl)-1,2,3,6,7,11b-hexa-
hydro-4H-pyrazino-(2,1-α), (Fig. 1), marketed under the 
brand name Biltricide, is a bitter-tasting white crystalline 
powder. Under normal storage conditions, this drug is stable 
and practically insoluble in water but soluble in some or-
ganic solvents. PZQ was first selected for its action against 
helminths in the mid-1970s, and was initially used in treating 
veterinary cestode and trematode infections; subsequently, it 
was and continues to be used in treating various trematode 
infections in humans [14]. Over the years, PZQ has remained 
the best mono-therapeutic agent and drug of choice for all 
forms of schistosomiasis due to its ready accessibility, inex-
pensiveness, safety, and high efficacy [11, 15, 16]. However, 
its cure rate of only 60% to 95%, inability to hinder re-
infection [17, 18], ineffectiveness against the juvenile stage 
of the parasite [19], and resistance have raised concerns. 
To date, the mechanism of action of PZQ still remains a 
mystery, thus many researchers have suggested ways in 
which the drug may be responsible for the parasite’s death. 
In 2001, Kohn and colleagues [20] hypothesized the drug has 
a negative effect on the Ca
2+
 homeostasis of the worm. They 
speculated that PZQ allows the opening of several channels 
that lead to the disruption of the interface between the α1/β 
inside Ca
2+ 
voltage gated channel. Other reports have sug-
gested that PZQ induces muscle contraction and disruption 
of the tegument system resulting in antigen presentation [21, 
22]. PZQ is lipophilic and its action on worm-antigen during 
exposure may be associated with its interaction on the hy-
drophobic areas of the tegumental outer membranes [23]. 
The cure rate for S. mansoni ranges between 60% and 
99%. For instance, 25mg/kg bodyweight in two oral doses 
every 4 hours achieves a cure rate between 63% and 97%. A 
single oral dose of 40mg/kg bodyweight attains a 72% to 
100% cure rate, while 20mg/kg of three divided oral doses 
every 4 hours kill 71%-99% of the parasites. Yet, a 78.6% to 
a 90% cure rate may be attained with a single dose of 
40mg/kg, while an 84.6% to 98% decrease in egg output 
among non-cured individuals may be achieved [24]. Intra-
muscular, oral and intradermal administration of this drug is 
said to be effective. It is generally a well-tolerated and non-
toxic drug. However, nausea, vomiting, hepatomegaly and 
headache are some of the known negative side effects [25]. 
 
Fig. (1). Chemical structure of Praziquantel. (A higher resolution / 
colour version of this figure is available in the electronic copy of 
the article). 
3. PAST AND PRESENT DRUGS USED IN THE 
TREATMENT OF SCHISTOMIASIS 
3.1. Metrifonate 
Historically, metrifonate (Fig. 2) was used in treating uri-
nary schistosomiasis but the administration of multiple doses 
in the course of treatment made the drug to lose public ap-
proval and acceptance [26]. Metrifonate is an organophos-
phorous, 0,0-dimethyl-2,2,2-trichloro-hydroxyethyl-phos-
phonate, previously known as trichlorphone and trichlorfone. 
This compound has variable and selective anti-Schistosoma 
haematobium activity, due to its incomplete metabolism as 
an effective acetylcholinesterase inhibitor and organophos-
phate (dichlorvos). In 1991, Shekhar [27] reported that this 
drug was the best in treating urinary schistosomiasis caused 
by S. haematobium but sadly, it showed no activity against 
other species parasitizing humans [28].  
The mechanism of action behind this drug exhibiting 
anti-S. haematobium action is still a mystery. However, an 
early study by James and colleagues [29] suggested that the 
inhibition of acetylcholinesterase by metrifonate leads to 
sweeping of the worm to the lungs where they cannot de-
velop. The results showed that 40% of S. haematobium 
worms were found in the lungs and 60% in the liver but there 
was an increase in the quantity of the S. haematobium in the 
lungs after metrifonate exposure for 2 or 3 days. It was con-
cluded that after 5 days of metrifonate treatment, there was a 
significant decrease in the quantity of S. haematobium. But, 
the death of the pharmacologically damaged parasite could 
also be assumed to be a result of physical factors, inadequate 
supply of nutrients or by possible cell-mediated mechanisms 
of cytotoxicity due to the abundance of immunocompetent 
cells like alveolar macrophages and eosinophils presence in 
the lungs [30]. One study suggested that metrifonate can 
cause a stunning effect on the adult parasite. According to 
Shekhar [27], the S. haematobium worms are stuck, enclosed 
and killed in the arterioles of the lungs after being stunned. 
Moreover, the prescribed oral dosage of metrifonate is 
7.5mg/kg to 10mg/kg thrice and it must be administered two 
weeks apart [30]. In the course of treatment, metrifonate 
roughly decreases 90-95% of the parasite eggs and a 44% to 
93% cure rate is attainable in treated individuals [31]. Metri-
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fonate use can result in minor side effects such as diarrhoea, 
vomiting, colic, and nausea. Other effects include tiredness, 
vertigo, syncope, headache, myasthenia, bronchial spasms, 
sweating and muscular tremor. To date, this drug has been 
withdrawn from the market as a result of economic, opera-
tional and medical standards [32, 33]. However, with optimi-
zation, it can be reassessed as the medication or alternative 
drug for urinary schistosomiasis [34]. 
 
Fig. (2). Chemical structure of Metrifonate. (A higher resolution / 
colour version of this figure is available in the electronic copy of 
the article). 
3.2. Oltipraz 
Oltipraz (OPZ), (Fig. 3), is a synthetic dithiolthione 
(C8H6N2S3; 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione) 
which is similar in structure to the dithiolthiones found in 
cruciferous vegetables. In humans, OPZ can be used against 
infections caused by S. intercalatum, S. mansoni, and S. 
haematobium. Nare and colleagues [35] reported that the 
action of this drug against schistosomiasis is very slow, tak-
ing approximately 2 months to cure. Although the mode of 
action of this drug is poorly understood, it is assumed that 
after nine days of use it causes a hepatic shift that moves the 
parasite to the liver from the mesenteric veins [36]. Exposure 
of the worm to OPZ causes a reduction in glutathione syn-
thetase (GSS) levels [36, 37], which is assumed to interfere 
with the metabolism and possible elimination of the worm 
by the host immune system, probably by decreasing protec-
tion against the reactive oxygen intermediates [38]. Other 
studies have documented that OPZ assists the host to in-
crease its detoxification ability [36, 39]. According to Shek-
har [27], an oral dose of OPZ, 3.0 g to 4.5 g three times a day 
for curative treatment and a dose of 35 mg/kg twice a day 
only produces 90% cure in S. mansoni infected individuals. 
Gentilini and colleagues [40] stated that a dose of 1.25 to 
4.50g should be administered for S. intercalatum infection 
for 3 days to achieve a cure rate of 76.5% to 92%. While on 
the other hand, a dose of 25mg/kg should be administered for 
1 or 2 days to achieve a cure rate of 86% to 94% in S. 
haematobium infected persons [40]. Nausea, vomiting, 
weakness, stomach pain and insomnia are the frequent side 
effects of OPZ. At present, OPZ is currently not available in 
the market for schistosomiasis treatment again due to its in-
duced photosensitivity [39]. 
3.3. Niridazole 
Niridazole (1-(5-nitro-1,3-thiazol-2-yl)imidazolidin-2-
one (Fig. 4), is an orally administered anti-schistosomal 
agent, which shows activity against all the three major schis-
tosome species [41]. This drug is shown to be an effective 
long-lasting suppressor of delayed intolerance [42]. In addi-
tion to its anti-schistosome effects, Moczon and Swiderski 
[43] documented that this drug destroys schistosomes by 
decreasing glycogen levels of the parasite, thereby inhibiting 
glucose and lactate uptake and is also responsible for the 
degeneration of the female reproductive system. This drug 
acts by taking up [14C]-niridazole which binds covalently 
and leads to nitro-reduction and subsequent bond formation 
with the parasite macromolecules [44, 45, 46]. 
The prescribed dose is 25mg/kg each day for a week or 
35mg/kg daily for 5 days [45]. It shows more activity against 
S. haematobium infections with 80%-100% cure rate mostly 
in children and approximately 50% and 30%-70% cure rate 
in S. japonicum and S. mansoni infections respectively. Niri-
dazole side effects include vertigo, skin rashes, non-specific 
destruction of the T waves in the electrocardiogram (ECG), 
nausea, diarrhoea, brown urine and vomiting. Other unpleas-
ant effects include the central nervous system (CNS) and 
renal toxicity besides alteration of digestive and cardiac 
functions [47]. An in vivo study by Urman and co-workers 
[48] showed that this drug is carcinogen. Therefore, due to 
the many adverse effects attributed to this drug, the populace 
and medical practitioners have abandoned it in the treatment 
of schistosomiasis. 
 
Fig. (4). Chemical structure of Niridazole. (A higher resolution / 




hyl-7-nitro-1,2,3,4 tetrahydroquinoline), Fig. (5) is the only 
drug active against S. mansoni worms, particularly the male 
parasite, but has no effect on S. haematobim or S. japonicum 
worms [49]. This is due to the fact that the conversion of this 
 
Fig. (3). Chemical structure of Oltipraz. (A higher resolution / 
colour version of this figure is available in the electronic copy of 
the article). 
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drug to its active form requires the activity of sulfotrans-
ferase [50], which is only available in the S. mansoni para-
site. When converted to its active state (sulfate ester), it dis-
sociates non-enzymatically and alkylates schistosome DNA 
leading to the inhibition of nucleic acid production, disrup-
tion of protein synthesis, delayed destruction and death of 
the parasites [46, 51]. Over the last two decades, this drug 
has been the main drug for treating S. mansoni infection in 
South America [52]. However, resistance to oxaminiquine 
has been reported in Brazil [53], which may be as a result of 
alteration in the schistosome gene that encodes the esterify-
ing enzyme [54]. Currently, praziquantel has replaced 
oxaminiquine as a schistosomicide, not only because of its 
effectiveness but also largely due to its cost effectiveness 
[52]. For three consecutive days, oral doses of 20mg/kg 
bodyweight of oxaminiquine can be administered and de-
pending on the geographic area, this dose provides a cure 
rate of 80-90%. Some of the negative side effects of this 
drug include fever, headache, drowsiness, dizziness, convul-
sions and occasional orange-red urine discoloration.  
 
Fig. (5). Chemical structure of Oxamniquine. (A higher resolution / 
colour version of this figure is available in the electronic copy of 
the article). 
3.5. Mefloquine 
Mefloquine (Fig. 6), an aryl-amino-quinoline used in the 
treatment of malaria, has been reported to show effective 
activity against various stages of the schistosome parasite in 
vivo [55]. In 2008, this antimalarial was used for the first 
time to treat schistosomiasis by Van Nassauw and colleagues 
[56] who documented that a dose of 150 mg/kg caused a 
significant reduction in S. mansoni eggs in infected mice 
[56]. In vivo investigations further revealed that mefloquine 
shows good activity against S. mansoni at a single dose of 
200 mg/kg resulting in 72.3% total worm burden reduction 
[57]. On the contrary, oral administration of a higher dose at 
400 mg/kg achieved 86.7% and 95.1% worm burden reduc-
tion of both immature and mature female worms in infected 
mice [58]. Although the mechanism of its anti-schistosomal 
activity has not been investigated, interference with the di-
gestion of hemoglobin and raising intravacuolar pH, have 
both been suggested to play a role in its mechanism of action 
against Plasmodium [59]. In addition, mefloquine possesses 
a wide range of antimicrobial activity as it shows activity 
against larval and adult stages of Brugia malayi and Brugai 
patei [58]. It has a high tolerability rate in children and 
adults with dose-dependent negative effects like gastrointes-
tinal disorders and neuropsychiatric side effects [60]. There-
fore, the efficacy of mefloquine in the treatment of schis-
tosomiasis deserves further and extensive study. 
 
Fig. (6). Chemical structure of Mefloquine. (A higher resolution / 
colour version of this figure is available in the electronic copy of 
the article). 
3.6. Artemisinin 
Artemisinin (qinghaosu), (Fig. 7), is a key ingredient ex-
tracted from Artemisia annua plant leaves, a plant endemic 
to China, USA, Argentina and Central Europe [61]. It is a 
sesquiterpene lactone possessing a peroxide bridge that is 
considered to be the active pharmacophore. This compound 
constitutes a class of potent drugs used in the treatment of 
malaria which is known for their good safety profile and 
tolerance [62, 63]. Thus far, artemisininbased combination 
therapies (ACTs) have been documented as the most potent 
antimalarial drugs [64]. Interestingly, artemisinin derivatives 
such as artemether, artesunate, dihydroartemisinin and ar-
teether have been reported in several studies to possess anti-
schistosomal activity, both in human and animal experiments 
[65-67]. In areas of highly endemicity such as in China and 
Cote d’Ivoire, S. japonicum and S. mansoni infections have 
been effectively controlled with the administration of arte-
mether in human trials [68]. 
In contrast to PZQ, which shows the highest activity 
against adult worms [69, 70], artemether shows the highest 
activity against the juvenile worms of the three main species 
affecting humans, while leaving the invasive and adult stages 
of the worm less vulnerable [71, 72]. Thus, joint treatment 
with PZQ and artemether would cover the entire lifetime of 
the parasite in its definitive host [73] because once PZQ kills 
the adult worms, artemether will then subsequently kill the 
surviving schistosomula, which would have repopulated the 
host resulting in the abolishment of reinfection. Therefore, it 
was concluded that ACTs stimulate the destruction of both 
the juvenile parasite tegument and adult parasite [74].  
Moreover, artemisinin derivatives can affect the gut heme 
in the parasite resulting in heme alteration to an unstable 
species which can generate reactive oxygen species (ROS) 
with subsequent worm death [75]. A dose of 6mg/kg is given 
once in every 2-3 weeks [76]. 
 
Fig. (7). Chemical structure of Artemisinin. (A higher resolution / 
colour version of this figure is available in the electronic copy of 
the article). 
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3.7. Hycanthone 
Hycanthone, 1-(2-(diethylamino) ethylamino)-4(hydro-
xymethyl)-thioxanthen-9-one (Fig. 8), is a hydroxylated ver-
sion of lucanthone. Although this drug is no longer in clini-
cal use, studies have documented that when administered in 
a single intramuscular dose of 3 mg/kg, hycanthone is effec-
tive against S. mansoni and S. haematobium parasites [77] 
but shows no activity against S. japonicum worms [78]. Ac-
cording to Cioli and Knopf [79], male parasites are more 
susceptible to this treatment than females. In mice, the he-
patic shift hits the highest point at approximately 6 days 
post-treatment [80]. It is believed that this drug irreversibly 
binds to acetylcholine receptors, therefore paralyzing the 
digestive system of the parasite, leading to starvation, fol-
lowed by the death of S. mansoni worms [81]. During hycan-
thone therapy, Senft and co-workers [82] observed loss of 
hemoglobin pigment from the gastrointestinal tract, weaken-
ing of the tegument, and a decrease in blood volume, as well 
as body size in S. mansoni worms. However, it was also ob-
served that this drug can be carcinogenic and can induce 
liver damage [83, 45].  
 
Fig. (8). Chemical structure of Hycanthone. (A higher resolution / 
colour version of this figure is available in the electronic copy of 
the article). 
3.8. Combined Chemotherapy for Schistosomiasis 
Combination therapy was first used in the treatment of 
tuberculosis and subsequently it has been adapted for cancer, 
AIDs, malaria and Schistosomiasis; basically to delay the 
development of drug resistance and accomplish an addi-
tive/synergism therapeutic effect [32, 85]. This is imperative 
because once an addictive/synergism effect is presented, 
getting similar or higher efficacy at lower doses with tran-
sient side effect can be attainable. According to Gouveia et 
al. [85], when combining drugs for schistosomiasis, the 
drugs should possess a different mode of action to PZQ and 
target the juvenile worm to reduce egg burden and enhance 
cure. Rational combination of an artemisinin derivative with 
another anti-malarial drug with contrasting mechanism of 
action was employed in effective prevention of appearance 
and spread of drug resistance in Southeast Asia, which might 
have influenced the stoppage of falciparum malaria transmis-
sion in the area [86, 87]. 
Plethora researchers have combined PZQ and OXA to al-
leviate schistosomiasis. A study carried out in Malawi 
showed that combination of PZQ (15 – 20 mg/kg) and OXA 
(7.5 – 10 mg/kg) achieved significant reduction (about 93% 
to 99%) in the total number of schistosome eggs laid in 102 
schoolchildren infected with S. mansoni. Similarly, a 
markedly reduction (97% to 99.2%) in eggs laid was re-
corded in 56 schoolchildren infected with S. haematobium 
[88]. This finding is somewhat surprising because OXA has 
been well-known to show no activity against S. haemato-
bium. The combination was safe with only a few negative 
effects which were self-limiting. Equally, another study was 
conducted in Zimbabwe among 58 school aged children (7 to 
16 years) concurrently infected with S. mansoni and S. 
haematobium. Co-administration of these drugs was done in 
three doses (PZQ 8 mg/kg + OXA 4 mg/kg; PZQ 15 mg/kg + 
OXA 7.5 mg/kg and PZQ 20 mg/kg + OXA10 mg/kg), nota-
bly, PZQ 20 mg/kg + OXA10 mg/kg achieved a high cure 
rate of about 89% in children suffering from S. mansoni in-
fection. Interestingly, among the schoolchildren infected 
with S. haematobium treated with the varying doses of PZQ-
OXA combined therapy, there was no curative evidence al-
though there was a high reduction in egg count for both 
Schistosoma species (S. mansoni and S. haematobium) in 
schoolchildren in this study. Hence, it was concluded that the 
PZQ-OXA combination for the treatment of Schistosoma 
infection in the Zimbabwean children does not have curative 
advantage over the use of PZQ alone [89].  
In the early 1980s, artemisinin and its derivatives were 
discovered to show activity against schistosomes, particu-
larly the larval stage and this compound and its derivatives 
have assisted crucially in the prevention and treatment of 
human S. japonicum in China [90]. Thus, the combination 
therapy involving PZQ and artemisinin derivatives may be 
effective against all stages of the worm development, this 
treatment regimen may ultimately overcome the emergence 
of drug resistance recently experienced in the treatment of 
some cases of Schistosoma infection.  Different host-parasite 
models have been used to test the efficacy of PZQ and arte-
mether (ART) combined therapy. In rabbits infected with 
schistosomula and adult schistosomes, treatment with 50 
mg/kg of PZQ and 15 mg/kg of ART led to reduction in total 
worm burden (82%) which is significantly higher than re-
sults achieved from PZQ (66%) and ART (44%) monothera-
pies [91]. Adult rabbits infected with S. japonicum were used 
to confirm these results and PZQ-ART combination achieved 
96% - 99% total worm burden reduction and 99% - 100% 
female worm burden reduction [92]. Therefore, combination 
of PZQ and ART is safe at lower doses and more effective 
than PZQ and ART monotherapies. Administration of PZQ-
ART combined therapy in another study using mice experi-
mentally infected with different developmental stages of S. 
mansoni, recorded over 90% worm reduction with a remark-
able total absence of eggs from tissues and insignificant 
changes in the histopathology of the liver [93].  
In another study to ascertain the efficacy of PZQ and ar-
tesunate (AS), animal models were used. Remarkably, AS 
rendered the female worms sterile by impairing their fecun-
dity. Co-administration of PZQ and AS was found to signifi-
cantly reduce total worm count, total eradication of female 
worms and egg count on tissue [85]. Similarly, a non-blinded 
open-label treatment trial in Senegal enrolling 110 patients 
who were positive for S. mansoni infection. Patients in the 
age-range between aged 1 and 60 years was used to deter-
mine the efficacy of PZQ-AS combined therapy. Each per-
son was treated with either a single dose of PZQ (40 mg/kg), 
AS endorsed dose for malaria treatment (4 mg/kg followed 
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by 2 mg/kg × 4 daily dose), or a co-administration of these 
two drugs. At 5, 12 and 24 weeks after treatment, cure and 
egg reduction rates were assessed by examining two Kato-
Katz thick smears taken from a single stool sample. Northern 
Senegal is considered as one of the severe transmission areas 
of S. mansoni, hence, the rate of re-infection is high and 
rapid. In this regard, the curative efficacy achieved at 5weeks 
following treatment will be considered here. The PZQ-AS 
administration resulted in cure and decrease in the number of 
eggs (69% and 89%), which is higher than cure and egg re-
duction rate achieved with monotherapies of PZQ and AS 
[94]. 
Another study carried out in Nigeria by Inyang-Etoh and 
co-workers [95] where they administered PZQ-AS to treat 
urogenital schistosomiasis. Randomly, they selected school-
children aged 4 to 20 years and were treated with PZQ-
placebo, AS-placebo, PZQ (40 mg/kg), AS (4 mg/kg) or both 
40 mg/kg of PZQ and 4 mg/kg of AS. Co-administration 
achieved high cure (88.6%) and egg reduction rate (93.6%), 
conversely PZQ achieved cure rate of 72.7% while AS 
achieved 70.5% [95]. 
Furthermore, the efficacy of combined treatments using 
PZQ-mefloquine (MFQ) and MFQ-artemisinin derivatives 
have been investigated both in vitro and in vivo and in hu-
man clinical trials. El-Lakkany et al [96] reported the phar-
macodynamics of PZQ-MFQ in mice infected with S. 
mansoni. They showed that 200 mg/kg dose of PZQ and 200 
mg/kg of MFQ boosted therapeutic efficacy over PZQ dose 
alone by causing a great reduction in the total numbers of 
adult worms (PZQ-MFQ = 95%, PZQ alone = 49%), juve-
nile worms (PZQ-MFQ = 96%, PZQ alone = 29%) and a 
nearly complete elimination of immature eggs, juvenile fe-
males and adult females. The decrease in worm burden aided 
in repairing lesions on the hepatic granulomatous, restoration 
of liver histology and normalization of the liver function. In 
mice experimentally infected with S. japonicum, the efficacy 
of MFQ at a single dose, multiple doses or concomitant ad-
ministration with AS, ART or PZQ was examined 4 weeks 
following treatment [97]. Combined administration of 50 
mg/kg or 100 mg/kg of MFQ with either ART or AS 
(100 mg/kg) completely eradicated female parasite with 
MFQ-ART showing more curative efficacy. Better results 
were achieved with 100 mg/kg combined chemotherapy than 
sole chemotherapy. Combined therapy caused a significant 
reduction of total worm; 100 mg/kg each of MFQ and AS 
achieved 76.7% and 100 mg/kg each of MFQ and ART 
achieved 87.8% while sole therapies achieved; 100 mg/kg 
Table 1. Different anti-schistosomal drugs and their mechanisms of action. 










7.5mg/kg to 10mg/kg × 3 






S. intercalatum, S. 
mansoni and S. 
haematobium 
Mice 
(in vivo)  
3.0 - 4.5 g/day × 3. Curative 
treatment: 35 mg/kg/day × 
2 = 90% cure in S. mansoni.  
1.25 - 4.50g for 3 days in S. 
intercalatum. S. haemato-
bium, 25mg/kg × 1 or 2 
days 
Oral Causes hepatic shift [40, 27] 
Niridazole 
S. japonicum, S. 




25mg/kg each day × 1week 
or 35mg/kg daily × 5 days. 
Oral 
Takes up [14C]-niridazole, 
binds covalently leading to 
nitroreduction and subsequent 
bond formation with the para-
site macromolecules 
[44, 45, 46] 
Oxamniquine S. mansoni 
Mice 
(in vivo) 
20mg/kg × 3days Oral 
Converts to its active type 




S. japonicum, S. 




6mg/kg once every 2–3 
weeks 
Oral 
Affect the gut heme in the 
parasite resulting in heme 
alteration to an unstable spe-
cies which can generate ROS 
with subsequent worm death 
[75]. 
Praziquantel 
S. japonicum, S. 




Single dose of 40 mg/kg Oral 
Disruption worm Ca2+ homeo-
stasis 
Impairment of the worm tegu-
ment 
[84, 24, 20] 
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AS (59.8%) versus 100 mg/kg MFQ (67.9%) and 100 mg/kg 
ART (55.6%). The result proposes a synergistic effect be-
tween artemisinin and MFQ [97] (Table 1).  
4. OTHER DRUGS USED AGAINST SCHISTOSO-
MIASIS IN THE PAST AND POTENTIAL FUTURE 
DRUGS 
Mirazid is a commercial product extracted from myrrh, 
an aromatic gum resin. This extract was proposed as an al-
ternative to PZQ as it elicits anti-schistosomal activity by 
extravasation and uncoupling of the parasite [98]. Earlier 
studies have shown it to be a promising emerging drug with 
low toxicity relative to PZQ. For example, Sheir and col-
leagues [99] showed an initial 91.7% cure rate in S. mansoni 
at a dose of 10mg/kg three times daily and a 98.1% cure rate 
after 2 months of initial treatment (6mg/kg × 6 daily). How-
ever, throughout the years, results from various studies on 
this drug have been inconsistent, which has led to its use 
being stopped by the World Health Organisation (WHO) 
[100]. 
Meclonazepam (3-methylclonazepam), a derivative of 
benzodiazepine developed and patented in 1977 by 
Hoffman-La Roche, has also been demonstrated by experi-
mental investigations to possess anti-schistosomal activity 
and relatively long plasma half-life of approximately 40 
hours [101]. Studies have established that this drug is very 
effective against S. mansoni strains and its potency is similar 
to that of oxamniquine, hycanthone and niridazole [102]. A 
single dose of 0.3 mg/kg will successfully cure parasitic in-
fections with harsh side-effects like drowsiness, dizziness, 
slurred speech, ataxia, muscle weakness, reduced mental 
alertness, and lateral nystagmus [103]. 
5. THE USE OF NATURAL PRODUCTS AGAINST 
SCHISTOSOMIASIS 
For centuries, plants have not only been used to cater for 
the basic needs and livelihood of man such as food, shelter, 
clothing, biologically active products, fertilizers, flavours, 
fragrances, but also for curative purposes when used as 
medicines [104, 105]. Steadily old medicines are now be-
coming the modern and state-of-the-art drugs of today. It has 
been documented that more than 80% of Africa, Asia, and 
Latin America’s medicinal needs have depended heavily on 
traditional and herbal medicines [106]. However, modern 
technology and orthodox medicine are currently raising in-
terest and getting involved in these sources of alternative 
health care. However, in the absence of vaccine treatment for 
schistosomiasis, investigators are now considering natural 
products as new, inexpensive and effective alternatives to 
PZQ.   
Several plants have been used in traditional African 
medicine as molluscicides and for curing schistosomiasis 
[107]. Most of the plants that have been documented for their 
anti-schistosomal activities and potentials have mostly been 
in the form of indigenous knowledge passed down through 
numerous generations, mostly by traditional healers. A study 
by Ndamba and colleagues [108] successfully interviewed 
286 traditional healers from five provinces in Zimbabwe, 
with 85% of them registered with the largest association of 
traditional healers in the country– the Zimbabwe National 
Traditional Healers’ Association (ZINATHA) [108]. The 
traditional healers reported 47 anti-schistosomal plants, of 
which 8 were identified as those most commonly used for 
treatment based on the healers’ knowledge of the urinary 
form of schistosomiasis. These include Ximenia caffra (Ola-
caceae), Dicoma anomala (Compositae), Phaseolas vulgaris 
(Leguminosae), Lannea edulis (Anacardiaceae), Elephantor-
rhiza goetzei (Leguminosae), Abrus precatorious (Legumi-
nosae), Ozoroa insignis (Anacardiaceae), and Pterocarpus 
angolensis (Leguminosae).  
Furthermore, animal studies using extracts from these 
eight plants, showed the latter three plants presenting posi-
tive lethal activity against adult schistosomes. Further studies 
by Molgaard and co-workers [109] investigated 23 of these 
plants by testing their leaf, stem, root, fruit and bark extracts 
in vitro. Arbus precatorius and Elephantorrhiza goetzei ex-
hibited the best results against schistosomulae and this was 
attributed to the presence of natural compounds such as tan-
nins, steroids, terpenes, flavonoids and indole alkaloids in 
the Arbus species.  
Terpenoids e.g. (+)-limonene epoxide (extract from Cit-
rus sinensis), Tashinones (cryptotashinone, tanshinone I and 
IIA), alkaloids (e.g. imidazole alkaloid epiisopiloturine from 
Pilocarpus microphyllus), quinoline methanols (e.g. 
quinidine), flavanoids (alpinum isoflavone from Millettia 
thonningii), arachidonic acid (e.g. oils from Mortierella al-
pine) Quinones (e.g. plumbagin from Plumbago scandens) 
and other natural products such as Aspidin, Desaspidin, 
Flavaspidic acid and Anisomycin are a few examples of 
plant products that have shown activity against schistosomes 
[110].  
The schistosomicidal activity of some of these com-
pounds has been shown to disrupt the mating process, dimin-
ish egg production, and increases the chances of the worms 
dying as well as affect the parasite’s motor activity and 
tegument. Other potential anti-schistosomal natural products 
not only take into account the ability of the worm to migrate 
to different parts of the body and resist host immune re-
sponses, but also consider the ability of the compound itself 
to kill the worms, the duration taken to do so and any re-
versible effects once the drug has ceased from being used 
[111]. These natural products include Epiisopilotulorine 
(from Pilocarpus microphylus), Piplartine (Piper 
tubercalatum), Phytol (found in chlorophyll), Phlorogluci-
nols (Dryopteris species), Cinchona Alkaloids, Vernonia 
amygdalina (Asteraceae), Emetine (from Cephaelis ipe-
cacuanha), Mevinolin (Lovastatin), Plumbagin and 
Sangunarine.  
Familiar plants that have been used for several years as 
spices or general ingredients in food have also been tested 
and shown to exhibit anti-schistosomal properties. These 
include Allium sativum (garlic), pumpkin seeds, peppermint, 
olive leaves, wormwood, thyme, black walnut, berberine and 
endod, among others [112]. Garlic has shown activity against 
schistosomes by causing wrinkling and detrimental effects to 
the tegument of the worm and severe damage to the parasite 
tubercles by causing shortness and loss of the spines and 
thorns [98, 100]. Ginger (Zingiber officinal) on the other 
hand has been shown to not only kill adult worms, but to 
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also interfere with the production of eggs and worm recovery 
[98]. Recently, it has been demonstrated that the plant can 
also ameliorate oxidative stress by increasing chloram-
phenicol acetyltransferase (CAT) activity in the liver of in-
fected mice as well as cause an increase in glutathione 
(GSH) and superoxide dismutase (SOD) antioxidant levels 
just like PZQ [113]. Curcumin, the principal curcuminoid of 
turmeric from the Zingiberaceae, has been documented with 
other compounds such as vernodali, piplartina, artesunate, 
artemether, artemisina and avocado and soybean oils, to in-
duce the separation of the male from the female and to dis-
rupt the release of eggs [111, 114]. Other effects include the 
death of adult worms and a decrease in motor activity [110].   
Other compounds such as propolis (a glue-like substance 
that bees collect from plants and tree barks) have also been 
suggested to be effective in treating schistosomiasis when in 
synergy with each other natural products or with PZQ. Stud-
ies have shown administration of this substance to infected 
mice significantly reduced schistosomula and the number of 
eggs in the liver and intestines [115]. However, incomplete 
eradication was also observed and hence, it has been sug-
gested that propolis in conjunction with PZQ, could result in 
an effective anti-schistosomal agent. Added to this, a meflo-
quine-artesunate combination has shown effective anti-
schistosomal properties against S. haematobium infected 
children, especially since both compounds each exhibit anti-
schistosomal properties [116]. Additionally, this drug com-
bination can clear malaria infection and reduce schistosomia-
sis-related illnesses.  
6. EMERGING DRUGS IN FIGHTING SCHISTOSO-
MISIS 
Knowing that chemotherapy for schistosomiasis is still 
fragmentary; drug repurposing can be an alternative strategy 
to finding a cure for this acute disease. Drug repositioning 
involves investigating existing drugs and its application in 
treating non-related diseases for which they were not origi-
nally designed [117]. Although several researchers have 
studied various classes of drugs for anti-schistosomal effects, 
drugs used in treating cancers have also shown promising 
effects. For instance, miltefosine, an alkylphosphocholine 
with anticancer activities, showed significant activity against 
the larval and adult stages of the S. mansoni worm [118]. An 
in vivo study by Eissa and co-workers [119], showed milte-
fosine interfered with the S. mansoni lifecycle. A dose of 20 
mg/kg orally administered daily for five days in invasive, 
immature or mature S. mansoni infected mice, showed a sig-
nificant decrease in hepatic granulomata size and a reduction 
in worm burden [119]. Additionally, a related study showed 
that using miltefosine and lipid nanocapsules (LNCs) as oral 
nanovectors resulted in a potent anti-schistosomal effect and 
a significant worm burden decrease in invasive and imma-
ture S. mansoni infected mice [120]. 
More so, imatinib (Gleevec
®
) is a kinase inhibitor em-
ployed in treating chronic myeloid leukemia; a disease 
caused by constitutive expression of gastrointestinal stromal 
tumour and active c-Kit kinases or deregulated Abi kinase 
activity [121]. Lately, imatinib has attracted attention in 
schistosomicide drug discovery as a result of its in vitro time 
and dose-dependent effect in S. mansoni morphology and 
physiology [122, 123]. Beckmann and Grevelding [122] 
showed that this drug causes pathological changes in the 
gonad and gastrodermis in both male and female worms, 
which leads to the death of the parasite. Additionally, it has 
been shown to have a remarkable effect on both the ovary 
and testes. Thus, further research on kinases is indispensable 
because their inhibitors have the ability to interfere with 
schistosome biology, thereby making them an attractive 
compound in new schistosomicide discovery.  
Chlorambucil is another anticancer drug that has exhib-
ited anti-schistosomal activity. It is an alkylating agent used 
in the treatment of chronic lymphocytic leukemia, low-grade 
non-Hodgkins lymphoma and Hodgkin’s disease [124]. Ac-
cording to Eissa and co-workers [125], this drug has negative 
and favourable in vivo and in vitro activity on schistosomes. 
In an in vivo experiment, this drug expressed a significant 
decrease in all worm burdens, achieving the best results 
against the juvenile worm where it attained a decrease in 
intestinal egg count, hepatic egg count and total worm load 
of 89.2%, 86.7% and 75.8% respectively [125]. Furthermore, 
a progressive decrease was also displayed in the parasite’s 
viability in a dose-dependent manner [125]. 
7. UNIVERSAL STRESS PROTEINS (USPS) 
USPs are a group of proteins present in various organ-
isms that include fungi, archaea, bacteria, yeast, protists, and 
plants [126, 127]. Their up-regulation enables schistosomes 
to tolerate diverse and mainly harsh ambiences such as high 
salinity, toxic chemicals and high temperatures during its 
developmental cycle. However, in the human genome, the 
genes encoding USPs have not been characterized, therefore 
making USPs a potential drug target against schistosomiasis 
[128, 129]. Additionally, their absence from the human host 
makes them an interesting vaccine target for the disease. It 
has been suggested that the schistosomulum parasitic stage, 
which is more prone to oxidative stress than other parasitic 
stages due to the production of nitric oxide and hydrogen 
peroxide by the human host, voids the human immune re-
sponse through the action of USPs and goes through a transi-
tion in morphology and adaptation to a different environ-
ment, which are both needed for the survival of the parasite.  
8. ANTIMICROBIAL PEPTIDES (AMPS) 
AMPs are a subset of proteins that forms part of the in-
nate immune system [130, 131]. They serve as the primary 
defence line in many organisms and can act as signalling 
molecule, immunomodulatory agent, antitumor agent and 
drug delivery vector [132, 133]. One of the mechanisms 
schistosomes use is to reduce the efficacy of the host im-
mune system. However, AMPs have the ability of stimulat-
ing the immune system, thereby causing resistant to the dis-
ease. In addition, AMPs can scavenge the ROS produced by 
the schistosomes. In respect to their various mechanisms of 
actions and characteristics, AMPs was proposed as novel 
drug targets in drug design and discovery [7].  
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CONCLUSION 
Schistosomiasis is a disease that affects underprivileged 
rural communities particularly those located in areas where 
fishing and farming activities are the major occupations. 
Sadly, pharmaceutical companies have ignored developing 
drugs for this disease because it usually affects poor people 
from rural areas who cannot afford highly-priced drugs and 
good health systems. Therefore, it is important to develop 
new and affordable anti-schistosomal drugs that are structur-
ally and functionally different from PZQ so as to alleviate 
the pressure of existing drug resistance by the worm. Moreo-
ver, combined chemotherapy based on merging compounds 
such as artemether and PZQ would serve as an advantage as 
both would cover all developmental stages of the schisto-
some worm and the rapid development of PZQ resistance 
would be tackled. Overall, more detailed knowledge and 
understanding of the schistosome biology is needed in order 
to speed up the design and development of new drugs.  
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